Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

G. Lee



Author of

  • +

    P1.10 - Poster Session 1 - Chemotherapy (ID 204)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P1.10-050 - Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high risk patients with unresectable non-small cell lung cancer (ID 3045)

      09:30 - 09:30  |  Author(s): G. Lee

      • Abstract

      Background
      We investigated the efficacy and toxicity of a biweekly schedule of docetaxel and cisplatin in high risk patients with unresectable (stages IIIB–IV) non-small cell lung cancer (NSCLC).

      Methods
      In this study, 48 high risk patients with previously untreated locally advanced or metastatic NSCLC were administered combination chemotherapy consisting of docetaxel 40 mg/m[2] and cisplatin 40 mg/m[2]; both drugs were given biweekly, on days 1 and 15, every 4 weeks in an outpatient setting.

      Results
      A complete response, partial response, and stable disease were observed in 1 (2.1%), 30 [62.5%, 95% confidence interval (CI): 47.9–77.1%], and 4 (8.3%) patients. The median overall survival was 15.1 months (95% CI: 11.7–18.5) and the median time to progression was 7.5 months (95% CI: 6.4–8.6). The major toxicity was grade 3 anemia in 7 (14.6%) patients. Grade 3/4 neutropenia was observed in 5 (10.4%) patients. Among the non-hematologic toxicities, grade 3 infection and grade 3 diarrhea were observed in 5 (10.4 %) and 4 (8.3%) patients, respectively. No treatment-related mortality was found.

      Conclusion
      As a front-line chemotherapy for high risk patients with unresectable NSCLC in an outpatient setting, the biweekly schedule of docetaxel and cisplatin showed feasible efficacy with manageable grade 3–4 hematologic toxicities, comparable to the result of previous studies of triweekly or weekly schedules. Additional large randomized studies are needed to optimize the schedule and dosage of combination therapy with docetaxel and cisplatin in high risk patients with unresectable NSCLC.

  • +

    P1.13 - Poster Session 1 - SCLC (ID 200)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P1.13-007 - The Clinical Impact of Sum of the Maximum Standardized Uptake Value on pretreatment 18F-FDG-PET/CT in Small Cell Lung Cancer treated with Front-line platinum based chemotherapy (ID 3043)

      09:30 - 09:30  |  Author(s): G. Lee

      • Abstract

      Background
      The aim of this study was to investigate the clinical significance of sum of the maximum standardized uptake value on pretreatment positron emission tomography/computed tomography ([18]F-FDG-PET/CT) in patients with newly diagnosed small cell lung cancer (SCLC) treated with front-line platinum-based chemotherapy.

      Methods
      We retrospectively analyzed 93 SCLC patients from March 2005 to May 2013 who underwent pretreatment [18]F-FDG-PET/CT. The sum of the maximum standardized uptake value (sumSUV~max~) was measured in all malignant lesions up to a maximum of five lesions and a maximum of two lesions per organ according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

      Results
      Patients were divided into two groups according to the median value of sumSUV~max~ (46 patients, < 21.8; 47 patients, ≥ 21.8). Although no significant difference was found between low and high sumSUV~max~ group (low versus high sumSUV~max, ~87.9% versus 76.9%; p = 0.186) in response rate (RR) following front-line platinum based chemotherapy, the group with low sumSUV~max~ showed significantly better overall survival (OS) [low versus high sumSUV~max~, 18.9 months (95% CI, 15.3-22.6) versus 10.8 months (95% CI, 7.6-14.1); p = 0.002] as well as better progression free survival (PFS) [low versus high sumSUV~max~, 8.3 months (95% CI, 6.9-9.7) versus 6.2 months (95% CI, 5.8-6.6); p = 0.005], compared with the group with high sumSUV~max~. Moreover, multuvariate analysis revealed that high sumSUV~max ~alone was an independent poor prognostic factor for OS (HR 1.95, 95% CI 1.12-3.39; p = 0.018).

      Conclusion
      This study showed that the sumSUV~max~ in pretreatment [18]F-FDG PET/CT was significantly correlated with the OS and PFS in patients with SCLC treated with front-line platinum based chemotherapy.